Navigation Links
Onyx Pharmaceuticals Announces December 2009 Investor Events
Date:11/25/2009

EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December:

ASH Briefing

December 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET

Principal investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA. The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on December 7, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 25914947. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25914947 later in the day. The replay will be available on the Onyx website through January 7, 2010.

Analyst Briefing on Development Program

December 17, 2009 - 8:30 a.m. ET

Onyx management will host an overview of its development program on December 17, 2009 at 8:30 a.m. ET. The program will feature presentations on multiple tumor types by external clinical investigators and members of management. Subsequent to the prepared remarks, the company will conduct a Q&A session with panelists and members of the management team. Further details regarding Analyst Day, including webcast information, will be announced closer to the event.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®( )(sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... West Lebanon, NH (PRWEB) , ... January 18, ... ... announces the launch of the revolutionary Active Brake Technology (ABT), an innovative braking ... and stability. , Active Brake Technology addresses one of the biggest concerns of ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone ... choose the best drug option for each patient. Dentists have several general anesthesia alternatives ... outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and ... help everyone endure and pass through tough times, Dr. Bernie Siegel energizes listeners ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... music enthusiasts at the National Association of Music Merchants (NAMM) winter trade show, ... 22, 2017. , Etymotic’s ER•4® has long been the gold standard for high-definition, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Medic-CE , a Career ... professionals, has released four new continuing education courses as part of its Code3 ... an online classroom and meet the requirements of the National Continued Competency Program ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 Safe Rx ... of pharmacies based in Loveland, Colorado ... Vials (LPVs) in selected Good Day locations.     ... a cost-effective alternative for secure storage," said Milton ... less than the price of a cup of coffee, ...
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... , January 18, 2017 After ... people regarding the use of cannabis both for medical and ... are more Americans open to the use of cannabis, but ... sectors. According to Arcview Market Research, the North American legal ... 30% from the previous year. The research projects sales will ...
Breaking Medicine Technology: